Abstract
Objective: The objective of this study was to identify significant influences on physician recommendation for imatinib mesylate in chronic phase CML patients. Methods: Data were collected via a mail and Web survey of a random sample of 1,100 hematologists/oncologists. Physicians’ recommendations for imatinib were measured with a visual analog scale in response to a series of clinical vignettes. Linear multiple regression was used to test the model, with physician recommendations as the dependent variable. The independent variables included treatment characteristics, communication channels, physician characteristics, social system characteristics, and control variables. Results: A total of 305 responses was received, giving a response rate of 29%. The regression model was found to be significant. Perceived relative advantages in efficacy, peer influence, past experience, and academic affiliation were significant positive influences and transplant specialty was a significant negative influence on physician recommendation for imatinib mesylate in patients with chronic phase CML. Conclusion: Treatment characteristics, peer influence, and physician specialty had significant influences on physician recommendation for imatinib mesylate.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.